Company Overview
UltraGreen.ai operates in the fluorescence guided imaging sector, specialising in ICG vials and imaging equipment including the IC-Flow camera system. The company serves global markets across the Americas, EMEA, and APAC regions, with regulatory approvals for its Verdye product and IC-Flow camera across multiple countries.
Strong Financial Performance Drives Growth
UltraGreen.ai demonstrated robust financial results in 1H26, with adjusted revenue and PATMI rising 30.7% and 23.4% year-on-year to US$87.2 million and US$39.5 million respectively. These figures represent 47% and 44% of full-year forecasts, indicating solid progress towards annual targets.
The performance was primarily driven by the full-half impact of US vial average selling price increases implemented in 3Q25, combined with higher global vial volumes. The Americas region, which accounts for 75% of total revenue, experienced a significant 22% year-on-year increase in average selling price to US$173 per vial. This pricing power demonstrates the company’s strong market position and ability to pass through price adjustments effectively.
Volume Growth Across International Markets
Beyond pricing improvements, UltraGreen.ai achieved impressive volume growth, with global vial sales increasing 11% year-on-year to 589,511 vials. International expansion proved particularly successful, with ICG vial volumes in EMEA and APAC regions growing 24% and 45% respectively. This growth was supported by expanded regulatory approvals, with Verdye now approved in 43 countries compared to 35 previously, and the IC-Flow camera approved in 46 countries versus 40 previously.
The company’s profitability was further enhanced by higher interest income of US$2.47 million, representing approximately a 37-fold increase year-on-year, as management deployed cash reserves into interest-bearing instruments.
Investment Outlook and Catalysts
Phillip Securities Research maintains a Buy recommendation with a target price of US$1.91, slightly reduced from the previous US$1.92. The minor adjustment reflects higher administrative expenses related to increased headcount and employee share ownership plan costs, resulting in 5% reductions to FY26e and FY27e profit forecasts.
UltraGreen.ai currently trades at a FY26e price-to-earnings ratio of 16.4x. Key catalysts for future performance include progress on PerfusionWorks’ US FDA approval process and the strategic deployment of unspent IPO proceeds towards mergers and acquisitions and other capital initiatives.
Frequently Asked Questions
Q: What drove UltraGreen.ai's strong 1H26 performance?
A: The company's revenue and profit growth was primarily driven by US vial price increases implemented in 3Q25 that provided a full-half impact in 1H26, combined with higher global vial volumes and increased interest income from deploying cash into interest-bearing instruments.
Q: How much did vial prices increase in key markets?
A: The Americas region, which represents 75% of total revenue, experienced a 22% year-on-year increase in average selling price to US$173 per vial.
Q: What was the volume growth performance across different regions?
A: Global vial volumes increased 11% year-on-year to 589,511 vials, with particularly strong growth in international markets where EMEA volumes rose 24% and APAC volumes increased 45%.
Q: What is Phillip Securities Research's recommendation and target price?
A: Phillip Securities Research maintains a Buy recommendation with a target price of US$1.91, slightly reduced from the previous US$1.92 target.
Q: How did regulatory approvals contribute to growth?
A: New country approvals supported volume growth, with Verdye now approved in 43 countries (up from 35) and the IC-Flow camera approved in 46 countries (up from 40).
Q: What are the key catalysts investors should watch?
A: Key catalysts include progress on PerfusionWorks' US FDA approval process and the deployment of unspent IPO proceeds towards mergers and acquisitions and other capital initiatives.
Q: At what valuation is UltraGreen.ai currently trading?
A: The company is trading at a FY26e price-to-earnings ratio of 16.4x.
Q: Why was the target price reduced slightly?
A: The target price was lowered marginally to account for higher administrative expenses related to larger headcount and employee share ownership plan expenses, resulting in 5% reductions to FY26e and FY27e profit forecasts.
This article has been auto-generated using PhillipGPT. It is based on a report by a Phillip Securities Research analyst.
Disclaimer
These commentaries are intended for general circulation and do not have regard to the specific investment objectives, financial situation and particular needs of any person. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of any person acting based on this information. You should seek advice from a financial adviser regarding the suitability of any investment product(s) mentioned herein, taking into account your specific investment objectives, financial situation or particular needs, before making a commitment to invest in such products.
Opinions expressed in these commentaries are subject to change without notice. Investments are subject to investment risks including the possible loss of the principal amount invested. The value of units in any fund and the income from them may fall as well as rise. Past performance figures as well as any projection or forecast used in these commentaries are not necessarily indicative of future or likely performance.
Phillip Securities Pte Ltd (PSPL), its directors, connected persons or employees may from time to time have an interest in the financial instruments mentioned in these commentaries.
The information contained in these commentaries has been obtained from public sources which PSPL has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the “Research”) contained in these commentaries are based on such information and are expressions of belief only. PSPL has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in these commentaries are subject to change, and PSPL shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will PSPL be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages. The companies and their employees mentioned in these commentaries cannot be held liable for any errors, inaccuracies and/or omissions howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in these commentaries may contain optimistic statements regarding future events or future financial performance of countries, markets or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided in these commentaries.
Views and any strategies described in these commentaries may not be suitable for all investors. Opinions expressed herein may differ from the opinions expressed by other units of PSPL or its connected persons and associates. Any reference to or discussion of investment products or commodities in these commentaries is purely for illustrative purposes only and must not be construed as a recommendation, an offer or solicitation for the subscription, purchase or sale of the investment products or commodities mentioned.
This advertisement has not been reviewed by the Monetary Authority of Singapore.
